You are viewing an expired study

This study is not currently recruiting Study Participants on If you would like to find active studies please browse nearby listings below.

Click here to view additional nearby studies or search for clinical trials.

Portland, Oregon 97239

  • Lymphoma


RATIONALE: LMB-2 immunotoxin can locate cancer cells and kill them without harming normal cells. PURPOSE: This phase I trial is studying the side effects and best dose of LMB-2 immunotoxin in treating young patients with relapsed or refractory leukemia or lymphoma.

Study summary:

OBJECTIVES: Primary - Determine the maximum tolerated dose of LMB-2 immunotoxin in pediatric patients with CD-25 positive relapsed or refractory leukemia or lymphoma. - Determine the toxic effects of this drug in these patients. - Determine the pharmacokinetics of this drug, including the terminal elimination serum half-life, area under the curve, volume of distribution, and relationship to disease burden, in these patients. Secondary - Evaluate the immonogenicity of this drug in these patients. - Determine response in patients treated with this drug. - Determine changes in lymphocyte subsets, immunoglobulin levels, serum cytokines, and soluble cytokine receptor levels in patients treated with this drug. OUTLINE: This is a dose-escalation, multicenter study. Patients receive LMB-2 immunotoxin IV over 30 minutes on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression, neutralizing antibodies (i.e., > 75% of the activity of 1 µg/mL of LMB-2 immunotoxin), or unacceptable toxicity. Patients achieving complete remission (CR) receive 2 additional courses beyond CR. Patients with acute lymphoblastic leukemia also receive cytarabine and hydrocortisone intrathecally once monthly concurrent with restaging lumbar punctures. Cohorts of 3-6 patients receive escalating doses of LMB-2 immunotoxin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, a total of 12 patients are treated at that dose level. Patients are followed weekly for 1 month and then monthly thereafter. PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study within 2-4 years.


DISEASE CHARACTERISTICS: - Histologically confirmed diagnosis of 1 of the following: - Non-Hodgkin's lymphoma, including the following subtypes: - Lymphoblastic lymphoma - Burkitt's lymphoma - Large cell lymphoma - Adult T-cell leukemia/lymphoma - Cutaneous T-cell lymphoma - Peripheral T-cell lymphoma - Hodgkin's disease - Acute myeloid leukemia - Chronic myelogenous leukemia - Acute lymphoblastic leukemia (ALL) - More than 5% blasts in the bone marrow (i.e., M2 marrow classification) - Acute hybrid leukemia, including the following subtypes: - Mixed lineage leukemia - Biphenotypic leukemia - Undifferentiated leukemia - CD25-positive (CD25+) disease, meeting 1 of the following criteria: - More than 15% of malignant cells are CD25+ by immunohistochemistry with anti-CD25 antibody - More than 30% of malignant cells from a site are CD25+ by fluorescence-activated cell sorting analysis - Measurable or evaluable disease - Relapsed or refractory disease after at least 1 standard chemotherapy regimen AND 1 salvage regimen - No available alternative curative therapies - Ineligible for or refused hematopoietic stem cell transplantation OR disease activity that prohibits the required time to identify a suitable stem cell donor - No CNS leukemia or lymphoma, as evidenced by any of the following criteria: - Cerebrospinal fluid (CSF) WBC > 5/µl AND confirmation of CSF blasts - Cranial neuropathies secondary to underlying malignancy - CNS lymphoma detected by radiological imaging - Prior CNS involvement with no current evidence of CNS malignancy allowed - No isolated testicular ALL PATIENT CHARACTERISTICS: Age - 6 months to 21 years Performance status - ECOG 0-3 (≥ 12 years of age) - Lansky 40-100% (< 12 years of age) Life expectancy - Not specified Hematopoietic - Pancytopenia due to disease allowed - For patients without bone marrow involvement: - Absolute neutrophil count > 1,000/mm^3 - Platelet count > 50,000/mm^3 (transfusion independent) Hepatic - Bilirubin ≤ 2.0 mg/dL - AST and ALT ≤ 5 times upper limit of normal - Hepatitis B surface antigen negative - Hepatitis C antibody negative Renal - Creatinine clearance ≥ 60 mL/min OR - Creatinine, meeting the following age-related criteria: - ≤ 0.8 mg/dL (≤ 5 years of age) - ≤ 1.0 mg/dL (6 to 10 years of age) - ≤ 1.2 mg/dL (11 to 15 years of age) - ≤ 1.5 mg/dL (> 15 years of age) - Calcium 2.0-2.9 mmol/L Cardiovascular - Ejection fraction ≥ 45% by MUGA OR - Shortening fraction ≥ 28% by echocardiogram Pulmonary - Oxygen saturation ≥ 90% Other - Sodium 130-150 mmol/L - Potassium 3.0-5.5 mmol/L - Magnesium 0.5-1.23 mmol/L - HIV negative - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No clinically significant unrelated systemic illness that would preclude study participation - No conditions that would preclude study compliance - No serum that neutralizes > 75% of the activity of 1 μg/mL of LMB-2 immunotoxin in tissue culture (due to either anti-toxin or anti-mouse immunoglobulin G antibodies) - No active graft-vs-host disease (i.e., off immunosuppression) PRIOR CONCURRENT THERAPY: Biologic therapy - Prior autologous bone marrow transplantation (BMT) allowed - At least 100 days since prior allogeneic BMT - At least 1 week since prior colony-stimulating factors (e.g., filgrastim [G-CSF], sargramostim [GM-CSF], or epoetin alfa) Chemotherapy - At least 2 weeks since prior chemotherapy (4 weeks for nitrosoureas) except intrathecal chemotherapy - No other concurrent chemotherapy Endocrine therapy - Concurrent corticosteroids allowed provided the dose has been stable for the past week and does not increase during study treatment - Tapering or discontinuation of steroids allowed Radiotherapy - At least 3 weeks since prior radiotherapy unless < 10% of marrow is irradiated and measurable disease exists outside the radiation port Surgery - Not specified Other - Recovered from all prior therapy - At least 30 days since prior investigational agents - Concurrent oral supplementation to maintain normal electrolyte levels allowed - No concurrent anticoagulation therapy for disease-related conditions - No other concurrent investigational agents

Study is Available At:

Original ID:




Secondary ID:


Study Acronym:

Brief Title:

LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma

Official Title:

Pediatric Phase I Trial of LMB-2 for Refractory CD25-Positive Leukemias and Lymphomas

Overall Status:


Study Phase:

Phase 1



Minimum Age:


Maximum Age:

21 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

National Cancer Institute (NCI)

Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Primary Purpose: Treatment

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Alan S. Wayne, MD
Principal Investigator
National Cancer Institute (NCI)

Study Dates

Start Date:April 2004
Verification Date:February 2007
Last Changed Date:April 29, 2015
First Received Date:June 10, 2004

Study Outcomes

There are no available Study Outcomes

Study Interventions

Intervention Type:Biological
Name:LMB-2 immunotoxin

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:NIH
Agency Type:Lead Sponsor
Agency Name:National Cancer Institute (NCI)

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source:

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.